Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

75.76 -3.82 (-4.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates
Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per share... 
Via StockStory
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings To Watch: Illumina (ILMN) Reports Q1 Results Tomorrow
Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday afternoon. Here’s what to expect. 
Via StockStory
Assessing Illumina: Insights From 16 Financial Analysts
Via Benzinga
Demystifying Illumina: Insights From 11 Analyst Reviews
Via Benzinga
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
Via Benzinga
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
Via Benzinga
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Healthcare Stock for Long-Term Investors and 2 to Keep Off Your Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
How Do Investors Really Feel About Illumina?
Via Benzinga
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
Via Benzinga
3 Mid-Cap Stocks Walking a Fine Line
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
The Future of the Military: 10 Predictions for the Next Decade
The military landscape has always been a dynamic arena, shaped by technological advancements, geopolitical shifts, and evolving threats. As we stand in 2025, the world is on the cusp of transformative... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Energy
Exposures Artificial Intelligence Climate Electricity Generation
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV. 
Via Benzinga
Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock
Cramer looks at Illumina, Archer Aviation, NANO Nuclear Energy, Steris, Sixth Street Specialty Lending, Lam Research and Arista Networks. 
Via Benzinga
Nvidia Stock Reached All-Time Highs After Jensen Huang's CES Keynote — Will Next Week's GTC Spark Another Surge?
Jensen Huang will give a keynote speech at Nvidia's GTC conference next week. A keynote from Huang at CES earlier this year took Nvidia stock to highs. 
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes
Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected. 
Via Benzinga
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027. 
Via Benzinga
3 Reasons to Sell ILMN and 1 Stock to Buy Instead
What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many shareholders. This may have investors wondering how to approach the situation. 
Via StockStory
Illumina Stock Slammed As China Retaliates Against Trump's Tariffs
The company's gene-mapping products are now banned from import in China amid the escalating trade war between the U.S. and China. 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
US Firm Illumina Faces Setback as China Blocks Imports Amid Escalating Trade War
China banned imports of Illumina's gene sequencers as new U.S. tariffs took effect, cutting its market access while Chinese rivals gain ground in the biotech sector. 
Via Benzinga
Topics World Trade
Exposures Tariff
Biotech Stocks Had A Good Week Despite Crosscurrents
It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds. 
Via Talk Markets
Topics ETFs Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.